A Phase 2a/2b Randomized, Placebo-Controlled Clinical Study to Evaluate the Safety and Efficacy of MK-1942 as Adjunctive Therapy in Participants with Mild to Moderate Alzheimer’s Disease Dementia

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-504017-79-00

Acronym

MK-1942-008

Enrollment

Registered

2023-06-20

Start date

2023-02-14

Completion date

2023-08-10

Last updated

2023-07-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment of AD dementia

Brief summary

Change from baseline in the Alzheimer’s Disease Assessment Scale-11-item cognitive subscale (ADAS-Cog11) score at Week 12, Number of Participants Experiencing Adverse Events (AEs), Number of Participants Discontinuing Study Intervention Due to AEs

Detailed description

Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall score at Week 12, Change from baseline in the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total score at Week 12

Interventions

DRUGPlacebo to mk-1942 - Capsule 0 mg

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in the Alzheimer’s Disease Assessment Scale-11-item cognitive subscale (ADAS-Cog11) score at Week 12, Number of Participants Experiencing Adverse Events (AEs), Number of Participants Discontinuing Study Intervention Due to AEs	—

Secondary

Measure	Time frame
Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change (ADCS-CGIC) Overall score at Week 12, Change from baseline in the Alzheimer’s Disease Cooperative Study Activities of Daily Living (ADCS-ADL) Total score at Week 12	—

Countries

Italy, Spain

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026